{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:49:04Z","timestamp":1777528144695,"version":"3.51.4"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Huntington\u2019s disease is a rare, genetic, neurodegenerative disease characterized by a triad of cognitive, behavioral, and motor symptoms. The condition gradually results in increasing disability, loss of independence, and ultimately death. Our objective was to use United States claims data (which offer valuable insight into the natural history of disease) to compare the prevalent comorbidities of people with Huntington\u2019s disease against matched controls with Parkinson\u2019s disease or with no major neurodegenerative diseases (general population controls). We also assess medication use in people with Huntington\u2019s disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, observational study using data from the IBM MarketScan<jats:sup>\u00ae<\/jats:sup> Databases. Cases and controls were matched 1:1, and comorbidities were analyzed in each group during 2017. Medications were also assessed in the Huntington\u2019s disease cohort. Eligible cases had\u00a0\u2265\u00a02 diagnostic codes for Huntington\u2019s disease; controls had\u00a0\u2265\u00a02 codes for Parkinson\u2019s disease (with no record of Huntington\u2019s disease), or, for general population controls, no record of Huntington\u2019s disease, Parkinson\u2019s disease, amyotrophic lateral sclerosis, or dementia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 587 matched individuals were assessed in each cohort. Depression and anxiety were more common in Huntington\u2019s disease versus Parkinson\u2019s disease (odds ratios: 1.51 and 1.16, respectively). Other conditions more common in Huntington\u2019s disease included dementia, communication\/speech problems, dysphagia, and falls. The use of antidepressant (59.9%) and antipsychotic (39.5%) medications was frequent among Huntington\u2019s disease cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>These data highlight the prevalence of psychiatric, cognitive, communication, swallowing, and mobility problems in people with Huntington\u2019s disease, underscoring the need for holistic expert care of these individuals.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acn3.51252","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T03:37:00Z","timestamp":1605929820000},"page":"126-137","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Neuropsychiatric comorbidities in Huntington\u2019s and Parkinson\u2019s Disease: A United States claims database analysis"],"prefix":"10.1002","volume":"8","author":[{"given":"Lianna","family":"Ishihara","sequence":"first","affiliation":[{"name":"Roche Products Ltd Welwyn Garden City UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Oliveri","sequence":"additional","affiliation":[{"name":"Genesis Research Hoboken NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre UCL Queen Square Institute of Neurology University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.12.018"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381328-2.00013-4"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.02.003"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304636"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25717"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60974-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12574"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443738"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009070"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-011-0215-x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7060067"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2014.00135"},{"key":"e_1_2_9_16_1","unstructured":"GhoshR TabriziSJ.Clinical Aspects of Huntington's Disease. In: Nguyen H Cenci M editors. Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease Current Topics in Behavioral Neurosciences 2015. p. 3\u201331."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00078"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26011"},{"key":"e_1_2_9_20_1","volume-title":"A Physician\u2019s Guide to the Management of Huntington\u2019s Disease","author":"Nance M","year":"2011"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2011.05.006"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.106"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202135"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002461"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70373-8"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.06.007"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9598(08)70024-3"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30127-3"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00170"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-140124"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.818545"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09263-7"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110509"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22188"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.11.45"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0670-4"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.4.725"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.03.043"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.06.001"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-170247"},{"key":"e_1_2_9_42_1","unstructured":"Huntington Study Group.Huntington Study Group Data & Findings.2015. [11 February 2020]; Available from:https:\/\/huntingtonstudygroup.org\/tools\u2010resources\/hsg\u2010research\/"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.51252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.51252","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.51252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T07:57:43Z","timestamp":1693727863000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.51252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1002\/acn3.51252"],"URL":"https:\/\/doi.org\/10.1002\/acn3.51252","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"2020-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}